Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
IMV Inc
IMVIF
Healthcare
Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:IMVIF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(2)
•••
Breakthorough
X
View Profile
View Bullboard History
Comment by
Breakthorough
on May 12, 2021 9:40am
RE:RE:RE:Q1 Conference
If they update (asannounced) ovarian and Basket Trial, with proper data, and may be Spirel, it should be more rhan enough if data are good...
(1)
•••
Jthom376
X
View Profile
View Bullboard History
Comment by
Jthom376
on May 12, 2021 9:34am
RE:RE:Q1 Conference
My opinion was that I don't see anytuing that will bring a nice recovery to this stock. It's not bad but I don't see a recovery this year. But we will see. Just opinion and would love to
...more
(2)
•••
Breakthorough
X
View Profile
View Bullboard History
Comment by
Breakthorough
on May 12, 2021 9:11am
RE:Q1 Conference
Don't get your point...: Selected Upcoming Milestones Maveropepimut-S Q2 2021: Beginning of Phase 2B DLBCL trial Q2 2021: Translational and biomarker clinical update for ovarian cancer Q3 2021
...more
(1)
•••
Jthom376
X
View Profile
View Bullboard History
Post by
Jthom376
on May 12, 2021 8:56am
Q1 Conference
Doesn't seem to be any hope of recovery this year... COVID clinical studies have been all together removed from Q2. Still feels like a good long term INV if you were in at the current price
...more
(1)
•••
gardy
X
View Profile
View Bullboard History
Comment by
gardy
on May 11, 2021 2:15pm
RE:Same same old story
You nailed it on the head. This management team has become an epic failure for shareholders. What happened to Ovarian cancer, Animal health, Covid vacine ( what a joke ) etc, etc. Becoming nothing but
...more
(0)
•••
8inchlynch
X
View Profile
View Bullboard History
Comment by
8inchlynch
on May 11, 2021 9:14am
RE:Looks a pretty serious appointment
"Kalos" = "Good" in Greek...along with all these other pointslol
(2)
•••
Breakthorough
X
View Profile
View Bullboard History
Post by
Breakthorough
on May 11, 2021 7:40am
Looks a pretty serious appointment
Most recently Dr. Kalos served as Executive Vice President and Head of R&D at ArsenalBio, a synthetic biology-based cell therapy start-up where he led development of R&D and product
...more
(8)
•••
Will101
X
View Profile
View Bullboard History
Post by
Will101
on May 10, 2021 4:54pm
Same same old story
Management is playing the same card again......Diverting attention to a new clinical trial with results WAAAAY into the future, while all the other stories pumped in the last few years are either
...more
(1)
•••
Jthom376
X
View Profile
View Bullboard History
Comment by
Jthom376
on May 10, 2021 1:29pm
RE:RE:RE:RE:New Trial in Breast Cancer
Curious if there is a precedence for who funds these independent studies. Just curious if anyone had some history with these.
(258)
•••
qwerty22
X
View Profile
View Bullboard History
Comment by
qwerty22
on May 10, 2021 11:31am
RE:RE:RE:New Trial in Breast Cancer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308147/ Seems like an interesting new population this trial is targeting.
(258)
•••
qwerty22
X
View Profile
View Bullboard History
Comment by
qwerty22
on May 10, 2021 11:26am
RE:RE:New Trial in Breast Cancer
https://link.springer.com/article/10.1007/s10549-008-0164-5
(258)
•••
qwerty22
X
View Profile
View Bullboard History
Comment by
qwerty22
on May 10, 2021 10:10am
RE:New Trial in Breast Cancer
Interesting. What can you say about this? Ph1, Investigator lead, so early and IMV have no control over it. A bunch of clinical scientists see the potential of dpx as a treatment in a different role
...more
(2)
•••
Breakthorough
X
View Profile
View Bullboard History
Post by
Breakthorough
on May 10, 2021 8:19am
New Trial in Breast Cancer
IMVs Lead Immunotherapy to be Investigated in Breast Cancer Study will evaluate maveropepimut-S (formerly known as DPX-Survivac) with an aromatase inhibitor, with/without radiotherapy or
...more
(1)
•••
Jthom376
X
View Profile
View Bullboard History
Comment by
Jthom376
on May 09, 2021 6:21pm
RE:RE:RE:RE:Anybody speak with management lately?
It was their fiscal 2020 financial report. So thru December 31 2020. I do believe they are being held up... otherwise they'd be foolish not to continue collecting free money. Maybe I'm wrong
...more
(258)
•••
qwerty22
X
View Profile
View Bullboard History
Comment by
qwerty22
on May 09, 2021 12:04pm
RE:RE:RE:Anybody speak with management lately?
What months did that Q cover? Initially the preclinical work is relatively cheap. It probably only starts to scale up when you do manufacturing, toxicology and animal challenge studies. If those
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >